202 related articles for article (PubMed ID: 24469044)
1. The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2.
Essers PB; Klasson TD; Pereboom TC; Mans DA; Nicastro M; Boldt K; Giles RH; MacInnes AW
Oncogene; 2015 Feb; 34(6):771-9. PubMed ID: 24469044
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
[TBL] [Abstract][Full Text] [Related]
3. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
4. p53 stabilization and transactivation by a von Hippel-Lindau protein.
Roe JS; Kim H; Lee SM; Kim ST; Cho EJ; Youn HD
Mol Cell; 2006 May; 22(3):395-405. PubMed ID: 16678111
[TBL] [Abstract][Full Text] [Related]
5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
6. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
8. Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein.
Rao H; Li X; Liu M; Liu J; Li X; Xu J; Li L; Gao WQ
Oncogene; 2020 May; 39(19):3853-3866. PubMed ID: 32161311
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
10. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
[TBL] [Abstract][Full Text] [Related]
11. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
12. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
[TBL] [Abstract][Full Text] [Related]
13. The positive regulation of p53 by the tumor suppressor VHL.
Roe JS; Youn HD
Cell Cycle; 2006 Sep; 5(18):2054-6. PubMed ID: 16969113
[TBL] [Abstract][Full Text] [Related]
14. The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel-Lindau tumor suppressor.
Falconieri A; Minervini G; Bortolotto R; Piovesan D; Lopreiato R; Sartori G; Pennuto M; Tosatto SCE
Sci Rep; 2020 Sep; 10(1):15850. PubMed ID: 32985545
[TBL] [Abstract][Full Text] [Related]
15. Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL).
Liu X; Cai X; Hu B; Mei Z; Zhang D; Ouyang G; Wang J; Zhang W; Xiao W
J Biol Chem; 2016 Dec; 291(49):25692-25705. PubMed ID: 27777301
[TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
17. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
[TBL] [Abstract][Full Text] [Related]
18. PDCD5 interacts with p53 and functions as a positive regulator in the p53 pathway.
Xu L; Hu J; Zhao Y; Hu J; Xiao J; Wang Y; Ma D; Chen Y
Apoptosis; 2012 Nov; 17(11):1235-45. PubMed ID: 22914926
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
20. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
